Clinical Trial: Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07331545) titled 'Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults' on Dec. 29, 2025.

Brief Summary: This is a first-in-human, Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 following single and multiple ascending subcutaneous doses in healthy Chinese adults. The study consists of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). Participants will be randomly assigned to receive either QL2401 or placebo. The primary objective is to assess safety and tolerability. Secon...